CNS Therapeutics Target a highly specialized CNS injury pipeline with AXER-204 and position ReNetX Bio as a partner for academic medical centers and biotech firms pursuing first-in-class neuroregenerative therapies.

Clinical Progress Leverage proximity to Phase 2 development to offer strategic collaborations, joint research opportunities, and milestone-based partnerships with CROs, contract manufacturers, and translational science groups.

Strategic Partnerships Engage with organizations focusing on spinal cord injury, glaucoma, and traumatic brain injury to explore co-development, licensing, or funded research programs that align with ReNetX’s growth and capital needs.

Resource Constraints With a small team and modest revenue, propose scalable, low-risk deals such as milestone-driven collaborations, advisory roles, or sponsored research to de-risk investment while accelerating pipeline progress.

Funding Readiness Highlight the existing $9.8M in funding and recent awards to attract non-dilutive funding conversations, government grants, and strategic investors seeking early-stage, high-traction CNS biotech opportunities.